MMP Inhibitor For Orofacial Pain
MMP 抑制剂治疗口面部疼痛
基本信息
- 批准号:8198109
- 负责人:
- 金额:$ 25万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-08-04 至 2013-07-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAnimal ModelAnimalsAstrocytesBehavioral ModelBiological AvailabilityChronicDoseDrug KineticsEnzymesGelatin ZymographyGelatinase AGelatinase BGoalsIntravenousLigationMatrix Metalloproteinase InhibitorMeasuresMechanicsMicrogliaModelingMolecularMusNational Institute of Dental and Craniofacial ResearchNeurosciencesOralOral AdministrationOrofacial PainPainPain DisorderPathologyPenetrationPharmaceutical PreparationsPharmacologic SubstancePhaseRattusRodent ModelRunningSmall Business Innovation Research GrantSpinalSpinal CordSpinal nerve structureTestingTissuesTrigeminal SystemWorkallodyniaanimal efficacyanimal paindorsal horngabapentininhibitor/antagonistmechanical allodyniamilligrammouse modelnovelorofacialpainful neuropathyscale up
项目摘要
DESCRIPTION (provided by applicant): Aquilus Pharmaceuticals, Inc. proposes to evaluate the effects of a novel matrix metalloproteinase (MMP) inhibitor on animal behavioral models of spinal and orofacial neuropathic pain. The goals for Phase I are to scale-up the synthesis of the inhibitor, determine its pharmacokinetics (PK) and then run animal efficacy studies in both the spinal nerve ligation (SNL)- mouse and rat trigeminal neuropathic pain animal models. The ultimate goal of the proposed work is to evaluate whether a matrix metalloproteinase inhibitor can be developed for the treatment of chronic orofacial pain.
PUBLIC HEALTH RELEVANCE: Aquilus Pharmaceuticals will evaluate an inhibitor to a group of enzymes that that have recently been discovered to be involved in the pathology of neuropathic pain. Aquilus will test this inhibitor in various animal pain models with a special emphasis on the treatment of chronic orofacial pain. If the project is successful, Aquilus Pharmaceuticals will be able to further develop this new inhibitor as a first in class treatment for orofacial pain without having any addictive or euphoric side effects.
描述(由申请人提供):Aquilus Pharmaceuticals,Inc.提出评估一种新的基质金属蛋白酶(MMP)抑制剂对脊髓和口面神经病理性疼痛的动物行为模型的影响。I期的目标是扩大抑制剂的合成,确定其药代动力学(PK),然后在脊神经结扎(SNL)-小鼠和大鼠三叉神经病理性疼痛动物模型中进行动物功效研究。这项工作的最终目标是评估是否可以开发一种基质金属蛋白酶抑制剂用于治疗慢性口面疼痛。
公共卫生关系:Aquilus制药公司将评估一组酶的抑制剂,这些酶最近被发现与神经性疼痛的病理学有关。 Aquilus将在各种动物疼痛模型中测试这种抑制剂,特别强调慢性口面疼痛的治疗。如果该项目成功,Aquilus Pharmaceuticals将能够进一步开发这种新的抑制剂,作为口腔面部疼痛的一流治疗方法,而不会产生任何成瘾或欣快的副作用。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
IRVING SUCHOLEIKI其他文献
IRVING SUCHOLEIKI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('IRVING SUCHOLEIKI', 18)}}的其他基金
Matrix Metalloproteinase-2/-9 Inhibitor For The Treatment Of ALS
用于治疗 ALS 的基质金属蛋白酶-2/-9 抑制剂
- 批准号:
9763774 - 财政年份:2019
- 资助金额:
$ 25万 - 项目类别:
Metalloproteinase Inhibitor For Pain and Morphine Tolerance Due To Thermal Injury
金属蛋白酶抑制剂,用于治疗热损伤引起的疼痛和吗啡耐受
- 批准号:
8639388 - 财政年份:2014
- 资助金额:
$ 25万 - 项目类别:
Selective Matrix Metalloproteinase Inhibitors For Osteoarthritis
用于骨关节炎的选择性基质金属蛋白酶抑制剂
- 批准号:
8383774 - 财政年份:2012
- 资助金额:
$ 25万 - 项目类别:
Development of a MMP Inhibitor for Neuropathic Pain
神经性疼痛 MMP 抑制剂的开发
- 批准号:
8903407 - 财政年份:2011
- 资助金额:
$ 25万 - 项目类别:
Development of a MMP Inhibitor for Neuropathic Pain
神经性疼痛 MMP 抑制剂的开发
- 批准号:
9115128 - 财政年份:2011
- 资助金额:
$ 25万 - 项目类别:
SYNTHESIS OF BETA-AMYLOID USING A NEW AFFINITY TECHNIQUE
使用新的亲和技术合成 β-淀粉样蛋白
- 批准号:
3028832 - 财政年份:1992
- 资助金额:
$ 25万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 25万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 25万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 25万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 25万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 25万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 25万 - 项目类别:
Adverse Effects of Using Laser Diagnostics in High-Speed Compressible Flows
在高速可压缩流中使用激光诊断的不利影响
- 批准号:
RGPIN-2018-04753 - 财政年份:2022
- 资助金额:
$ 25万 - 项目类别:
Discovery Grants Program - Individual